Ubidecarenone is under clinical development by BPGbio and currently in Phase I for Epidermolysis Bullosa. According to GlobalData, Phase I drugs for Epidermolysis Bullosa does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ubidecarenone LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ubidecarenone overview

Ubidecarenone is under development for metastatic pancreatic adenocarcinoma, breast cancer, refractory solid tumor, brain cancer, lymphoma, epidermolysis bullosa, recurrent high-grade glioma, anaplastic astrocytoma, gliosarcoma, and glioblastoma multiforme. The drug candidate is administered through topical and intravenous infusion routes. Ubidecarenone is a naturally occurring coenzyme structurally similar to vitamin K. The drug candidate is developed by NAi interrogative biology platform (AI driven platform).

It was also under development for the treatment of liver cancer, lupus, wounds, skin cancer, chemotherapy effects, leukemia, basal cell carcinoma and third line therapy of gastric cancer, colon cancer, kidney cancer (renal cell cancer), head and neck cancer, non-small cell lung cancer, malignant mesothelioma, bladder cancer, cutaneous squamous cell carcinoma and sarcopenia.

BPGbio overview

BPGbio is a clinical-stage biopharma company which uses AI to detect the risk of drug discovery for humanity. BPGbio is headquartered in Framingham, Massachusetts, the US.

For a complete picture of Ubidecarenone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.